Novavax
NVAX
165 hedge funds and large institutions have $350M invested in Novavax in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 47 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
11% less funds holding
Funds holding: 186 → 165 (-21)
26% less call options, than puts
Call options by funds: $9.73M | Put options by funds: $13.1M
38% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 47
78% less capital invested
Capital invested by funds: $1.59B → $350M (-$1.24B)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$35.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.4M |
| 3 |
JP Morgan Chase
New York
|
+$12.1M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$6.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$151M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$61.9M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$54.1M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$36.6M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$25M |
NVAX Hedge Fund Activity: Q3 2016 in Review
165 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q3 2016, worth a combined $350M — down 78% from $1.59B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of NVAX and 29 opened new positions — a net loss of 18 holders — while 41 trimmed existing stakes and 59 added.
The largest buyer was Millennium Management, adding an estimated $35.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $151M.
- 165 institutional investors held Novavax (NVAX) as of Q3 2016, down from 186 in Q2 2016.
- Funds reported $350M of Novavax stock for Q3 2016, down 78% quarter-over-quarter.
- 29 funds opened new Novavax positions in Q3 2016 and 47 closed out, a net change of -18 holders.
- The largest Novavax buyer in Q3 2016 was Millennium Management, an estimated $35.5M added.
- The largest Novavax seller in Q3 2016 was T. Rowe Price Associates, an estimated $151M sold.
Based on aggregated 13F filings for Q3 2016.